Related Experiment Video

Updated: Jul 10, 2026

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
08:36

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3

Published on: April 7, 2023

Phase 2 study of ABT-510 in patients with previously untreated advanced renal cell carcinoma

Scot Ebbinghaus1, Maha Hussain, Nizar Tannir

  • 1Arizona Cancer Center, Tucson, AZ, USA. Scot_Ebbinghaus@merck.com

Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|November 17, 2007
PubMed
Abstract

Insights

ABT-510 showed limited efficacy as a single agent for advanced renal cell carcinoma. Its favorable safety profile suggests potential for combination therapy in future studies.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • Angiogenesis is a key feature of renal cell carcinoma (RCC).
  • ABT-510 is an angiogenesis inhibitor designed to mimic thrombospondin-1's antiangiogenic effects.

Purpose of the Study:

  • To evaluate the safety and efficacy of ABT-510 in patients with advanced renal cell carcinoma.
  • Assessing progression-free survival (PFS), objective response rate, overall survival, and toxicity.

Main Methods:

  • Randomized trial of previously untreated patients with metastatic or unresectable RCC.
  • Two doses of ABT-510 administered subcutaneously twice daily in 28-day cycles.

Main Results:

  • Objective response rates were 4% (10 mg BID) and two unconfirmed partial responses (PRs) (100 mg BID).
  • Median PFS was 4.2 and 3.3 months, respectively. Median overall survival was approximately 27 months for both groups.
  • Most common adverse events included injection site reactions and fatigue. Grade 3/4 events were infrequent, with three bleeding episodes and one thrombotic event.

Conclusions:

  • ABT-510 demonstrated minimal clinical activity as a monotherapy for advanced RCC.
  • Further investigation of ABT-510 in combination therapy may be warranted due to its safety profile.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

Related Concept Videos

Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
Bioavailability Study Design: Healthy Subjects Versus Patients01:15

Bioavailability Study Design: Healthy Subjects Versus Patients

Bioavailability studies are essential for evaluating a drug's therapeutic efficacy and understanding its absorption patterns under various physiological conditions. Conducting such studies on target patient populations provides more relevant data by simulating real-world disease states. However, practical challenges often necessitate the use of young, healthy adult volunteers as study subjects.Patients may exhibit altered drug absorption patterns due to the effects of the disease itself,...
Drug Administration and Therapy Phases: Overview01:26

Drug Administration and Therapy Phases: Overview

Drugs, the chemical agents used in diagnosing, treating, or preventing diseases, undergo a four-phase process of development: pharmaceutic, pharmacokinetics, pharmacodynamics, and therapeutic.
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...